Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Zoe McBlain
Scotland North East and Cumbria
Your local GSK Gynae Oncology Representative is here to help with any questions you may have.
Great Britain
Indications
JEMPERLI is indicated in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.
JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.
Adverse events should be reported.
Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/ (UK) or search for MHRA Yellow Card in the Google Play or Apple App store.
Adverse events should also be reported to GSK Limited on 0800 221 441 or uksafety@gsk.com
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
January 2024 | PM-GB-DST-WCNT-230016 (V1.0)
